NCT06715982View on ClinicalTrials.gov

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

PHASE2RecruitingINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Immune Checkpoint Inhibitors (ICI)-Related Dermatitis

Interventions

DRUG

JAK Inhibitor

JAK inhibitors for 28 days

Trial Locations (1)

324000

RECRUITING

Quzhou people's hospital, Quzhou

All Listed Sponsors

lead

Shixiu Wu

OTHER